Vaxcyte, Inc. filings document a clinical-stage vaccine company developing bacterial-disease vaccine candidates and raising capital through registered common stock transactions. Recent Form 8-K reports cover financial results, business updates tied to VAX-31 and other pipeline programs, an underwritten common stock offering, an at-the-market sales agreement under an effective Form S-3 shelf registration, and a manufacturing services agreement for drug product supply.
Proxy materials disclose shareholder voting matters, board and governance information, executive compensation, and equity-plan matters. The filing record also identifies Vaxcyte’s Nasdaq-listed common stock under PCVX and formalizes material agreements, financing arrangements, and corporate disclosures related to its vaccine development and manufacturing strategy.
Vaxcyte, Inc. chief operating officer Jim Wassil reported open-market sales of 2,250 shares of common stock. On April 1, 2026, he sold 1,412 shares at a weighted-average price of $58.138 and 838 shares at a weighted-average price of $58.932.
After these sales, he directly owned 162,994 shares of Vaxcyte common stock. The transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025. A footnote also describes prior share transfers to his ex-spouse pursuant to a divorce settlement domestic relations order.
PCVX reported a resale transaction. James Wassil sold 7,395 shares of Common Stock on 03/10/2026 for $435,438.31, as shown on the notice filed by UBS Financial Services, Inc. The filing also lists RSU vesting amounts of 783 and 1,467 shares with vest dates in 2025.
Vaxcyte Inc Schedule 13G/A shows The Vanguard Group reporting 0 shares beneficially owned and 0% of the common stock following an internal realignment. The filing states certain Vanguard subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538, and was signed on 03/27/2026.
Vaxcyte, Inc. SVP, Finance & CAO Elvia Cowan reported selling 1,892 shares of common stock in open-market transactions. The sales on March 17, 2026 were executed under a Rule 10b5-1 trading plan adopted on December 8, 2025, with weighted-average prices of $55.387 and $56.263 per share.
After these sales, Cowan directly holds 28,975 shares of Vaxcyte common stock. The footnotes state that all transactions were within a pre-set trading plan and that no other shares subject to a January 29, 2026 lock-up agreement were sold.
PCVX Form 144 notice reports insider sales of Common Stock by Elvia Cowan. The filing lists a sale of 11,623 shares on 12/23/2025 for $556,971.85 and a sale of 2,500 shares on 03/11/2026 for $146,481.75.
The notice also records recent RSU vesting entries issued by the company on 02/28/2026 (432 shares), 03/02/2026 (580 shares) and 03/07/2026 (880 shares). The report is a near-term disclosure of transactions and issuer-issued vesting events.
Vaxcyte, Inc. Chief Technical Ops Officer Harpreet S. Dhaliwal surrendered 604 shares of common stock on March 9, 2026 to cover tax withholding obligations from vesting restricted stock units. The shares were delivered to the company rather than sold in the market, and Dhaliwal continues to hold 75,976 shares directly.
Vaxcyte, Inc. director and chief executive officer Grant Pickering reported a tax-related share disposition. On March 9, 2026, he surrendered 3,685 shares of Common Stock at $59.32 per share to cover tax withholding obligations from vesting restricted stock units.
After this withholding event, he directly held 496,939 shares of Vaxcyte common stock. Additional shares are held indirectly through trusts for the benefit of his children, and the filing notes that no other common shares subject to a January 29, 2026 lock-up agreement were sold.
Vaxcyte, Inc. president and CFO Andrew Guggenhime reported a routine tax-withholding share disposition tied to RSU vesting. He surrendered 1,021 shares of common stock at $59.32 per share to cover tax obligations when restricted stock units vested, rather than selling shares in the open market.
After this transaction, he directly holds 104,395 common shares. An additional 61,850 shares are held indirectly through ALG 2025 GRAT HOLDINGS LLC, a grantor retained annuity trust entity for which he is annuitant and trustee. The filing states that no other locked-up shares were sold by him.
Vaxcyte, Inc. SVP, Finance & CAO Elvia Cowan exercised stock options and sold shares in a routine, partially pre-planned transaction. Cowan exercised options for 2,500 shares of common stock at $25.92 per share and then sold 2,500 shares at an average price of $58.5927 per share.
The filing also shows 495 shares of common stock were surrendered to Vaxcyte to cover tax withholding obligations upon RSU vesting, which is described as a non-market disposition. After these transactions, Cowan directly holds 30,867 shares of Vaxcyte common stock. The sale was carried out under a Rule 10b5-1 trading plan adopted on December 8, 2025, indicating it was pre-scheduled rather than opportunistic.
Vaxcyte, Inc. chief operating officer Jim Wassil reported recent stock transactions. On March 9, 2026, 975 shares of common stock were surrendered to the company to cover tax withholding obligations upon RSU vesting, which is an automatic, non-market disposition.
On March 10, 2026, he completed two open-market sales totaling 7,395 shares of common stock at weighted-average prices of $58.316 and $59.160. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025. After these transactions, he directly holds 166,818 shares of Vaxcyte common stock, indicating that he retains a substantial equity position.